Pharmala Biotech Holdings Inc. (MDXXF)
| Market Cap | 7.61M -53.0% |
| Revenue (ttm) | 540.16K +121.9% |
| Net Income | -1.51M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 513 |
| Average Volume | 13,610 |
| Open | 0.0715 |
| Previous Close | 0.0687 |
| Day's Range | 0.0715 - 0.0715 |
| 52-Week Range | 0.0614 - 0.1907 |
| Beta | 0.77 |
| RSI | 47.03 |
| Earnings Date | Apr 29, 2026 |
About Pharmala Biotech Holdings
Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada. [Read more]
Financial Performance
In fiscal year 2025, Pharmala Biotech Holdings's revenue was 605,498, a decrease of -41.51% compared to the previous year's 1.04 million. Losses were -2.18 million, 164.1% more than in 2024.
Financial numbers in CAD Financial StatementsNews
PharmAla Announces Changes to Board of Directors
TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and man...
PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research
TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and man...
PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance
TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manuf...
PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules
TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manuf...
PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital
TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and man...
PharmAla Launches Nexus Portal for MDMA Prescribers and Therapists
TORONTO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and man...
PharmAla Completes Shipment of LaNeo™ MDMA to Johns Hopkins
TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and man...
PharmAla Partners with Veridion Group as Exclusive Distributor in New Zealand
TORONTO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla Completes Import of LaNeo MDMA for US Distribution
TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla Incorporates Australian Entity for Clinical Research
TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla Delivers MDMA to Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License
PharmAla delivers over 500 LaNeo MDMA capsules to Merhavim Psychiatric Hospital to be used in a clinical trial in exchange for IP rights to trial results
PharmAla Issues Q3 Financial Statements
TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla Files Preliminary Base Shelf Prospectus
TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manuf...
PharmAla Completes Shipment of LaNeo™ MDMA to Yale University, Provides Investor Update
PharmAla makes shipment to Yale, Agrees with Multidisciplinary Association for Psychedelic Studies to publicly post Investigator's Brochure for LaNeo MDMA
PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla
TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manuf...
PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufa...
PharmAla Issues Q2 Financial Statements
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and man...
PharmAla Contracts with Partner to Act as US Distributor
PharmAla sidesteps tariff risk and expands clinical operations in the United States by contracting with Sharp Clinical Services as distribution partner
PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington
TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands
TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla Completes Shipment of LaNeo™ MDMA to UCLA for Schizophrenia Study
TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
TORONTO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manuf...
PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
TORONTO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manu...